CYBA gene variants as biomarkers for coronary artery disease

Drug News and Perspectives

Volumn 23, Issue 5, 2010, Pages 316-324

  Moreno, Maria U ^a   Zalba, Guillermo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCLEROPROTEIN; CYBA PROTEIN, HUMAN; GENETIC MARKER;

APOPTOSIS; CELL GROWTH; CELL MIGRATION; CORONARY ARTERY DISEASE; CYBA GENE; GENE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MEDICAL RESEARCH; MUSCLE FIBER CONTRACTION; OXIDATIVE STRESS; REVIEW; ANIMAL; GENETICS; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CORONARY ARTERY DISEASE; GENETIC MARKERS; GENETIC VARIATION; HUMANS; NADPH OXIDASE; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77955896068     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.5.1437711     Document Type: Review

References (112)

1. Harrison, D., Griendling, K.K., Landmesser, U., Hornig, B., Drexler, H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003, 91(3A): 7A-11A.
2. Kaneto, H., Katakami, N., Kawamori, D. et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007, 9(3): 355-66. (Pubitemid 46145981)
3. Ando, K., Fujita, T. Metabolic syndrome and oxidative stress. Free Radic Biol Med 2009, 47(3): 213-8.
4. Cai, H., Harrison, D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87(10): 840-4.
5. Kojda, G., Harrison, D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999, 43(3): 562-71. (Pubitemid 29369255)
6. Droge, W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82(1): 47-95. (Pubitemid 34654215)
7. Madamanchi, N.R., Vendrov, A., Runge, M.S. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25(1): 29-38.
8. Beckman, J.S., Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996, 271(5 Pt 1): C1424-37.
9. Griendling, K.K., FitzGerald, G.A. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108(16): 1912-6.
10. Cave, A.C., Brewer, A.C., Narayanapanicker, A., Ray, R., Grieve, D.J., Walker, S., Shah, A.M. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006, 8(5-6): 691-728. (Pubitemid 44043102)
11. Zalba, G., San Jose, G., Moreno, M.U., Fortuno, M.A., Fortuno, A., Beaumont, F.J., Diez, J. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001, 38(6): 1395-9. (Pubitemid 34033422)
12. Forstermann, U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008, 5(6): 338-49. (Pubitemid 351761708)
13. Maytin, M., Leopold, J., Loscalzo, J. Oxidant stress in the vasculature. Curr Atheroscler Rep 1999, 1(2): 156-64.
14. Fortuno, A., San Jose, G., Moreno, M.U., Diez, J., Zalba, G. Oxidative stress and vascular remodelling. Exp Physiol 2005, 90(4): 457-62.
15. Zalba, G., Beaumont, J., San Jose, G., Fortuno, A., Fortuno, M.A., Diez, J. Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J Physiol Biochem 2000, 56(1): 57-64.
16. Nauseef, W.M. The NADPH-dependent oxidase of phagocytes. Proc Assoc Am Physicians 1999, 111(5): 373-82.
17. Bokoch, G.M., Knaus, U.G. NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci 2003, 28(9): 502-8.
18. Quinn, M.T., Gauss, K.A. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 2004, 7: 7.
19. Leto, T.L., Geiszt, M. Role of Nox family NADPH oxidases in host defense. Antioxid Redox Signal 2006, 8(9-10): 1549-61. (Pubitemid 44726330)
20. Geiszt, M. NADPH oxidases: new kids on the block. Cardiovasc Res 2006, 71(2): 289-99. (Pubitemid 43913736)
21. Bedard, K., Krause, K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87(1): 245-313. (Pubitemid 46209993)
22. Sumimoto, H., Miyano, K., Takeya, R. Molecular composition and regulation of the Nox family NAD(P)H oxidases. Biochem Biophys Res Commun 2005, 338(1): 677-86. (Pubitemid 41540615)
23. Sedeek, M., Hebert, R.L., Kennedy, C.R., Burns, K.D., Touyz, R.M. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 2009, 18(2): 122-7.
24. Cave, A. Selective targeting of NADPH oxidase for cardiovascular protection. Curr Opin Pharmacol 2009, 9(2): 208-13.
25. Selemidis, S., Sobey, C.G., Wingler, K., Schmidt, H.H., Drummond, G.R. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 2008, 120(3): 254-91.
26. Brandes, R.P., Schroder, K. Differential vascular functions of Nox family NADPH oxidases. Curr Opin Lipidol 2008, 19(5): 513-8.
27. Patel, R.P., Moellering, D., Murphy-Ullrich, J., Jo, H., Beckman, J.S., Darley-Usmar, V.M. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 2000, 28(12): 1780-94. (Pubitemid 30628665)
28. Lee, M.Y., Griendling, K.K. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal 2008, 10(6): 1045-59.
29. Thomas, S.R., Witting, P.K., Drummond, G.R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008, 10(10): 1713-65.
30. Frey, R.S., Ushio-Fukai, M., Malik, A.B. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 2009, 11(4): 791-810.
31. Ushio-Fukai, M., Nakamura, Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008, 266(1): 37-52. (Pubitemid 351753035)
32. Block, M.L. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 2008, 9 Suppl 2: S8.
33. Chan, E.C., Jiang, F., Peshavariya, H.M., Dusting, G.J. Regulation of cell proliferation by NADPH oxidase-mediated signaling: potential roles in tissue repair, regenerative medicine and tissue engineering. Pharmacol Ther 2009, 122(2): 97-108.
34. Channon, K.M., Guzik, T.J. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002, 53(4 Pt 1): 515-24.
35. De Minicis, S., Brenner, D.A. Oxidative stress in alcoholic liver disease: role of NADPH oxidase complex. J Gastroenterol Hepatol 2008, 23 Suppl 1: S98-103.
36. Droge, W. Oxidative stress and aging. Adv Exp Med Biol 2003, 543: 191-200.
37. Jones, R.D., Hancock, J.T., Morice, A.H. NADPH oxidase: a universal oxygen sensor? Free Radic Biol Med 2000, 29(5): 416-24.
38. Murdoch, C.E., Grieve, D.J., Cave, A.C., Looi, Y.H., Shah, A.M. NADPH oxidase and heart failure. Curr Opin Pharmacol 2006, 6(2): 148-53.
39. Segal, A.W. The function of the NADPH oxidase of phagocytes and its relationship to other NOXs in plants, invertebrates, and mammals. Int J Biochem Cell Biol 2008, 40(4): 604-18.
40. Yao, H., Yang, S.R., Kode, A. et al. Redox regulation of lung inflammation: role of NADPH oxidase and NF-kappaB signalling. Biochem Soc Trans 2007, 35(Pt 5): 1151-5. (Pubitemid 350206448)
41. Padmanabhan, S., Melander, O., Hastie, C., Menni, C., Delles, C., Connell, J.M., Dominiczak, A.F. Hypertension and genomewide association studies: combining high fidelity phenotyping and hypercontrols. J Hypertens 2008, 26(7): 1275-81.
42. Yende, S., Wunderink, R.G. Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease. Curr Opin Crit Care 2006, 12(5): 420-5. (Pubitemid 44341706)
43. Mayer, B., Erdmann, J., Schunkert, H. Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol 2007, 96(1): 1-7. (Pubitemid 46175364)
44. Fischer, M., Broeckel, U., Holmer, S. et al. Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction. Circulation 2005, 111(7): 855-62.
45. Kaess, B., Fischer, M., Baessler, A. et al. The lipoprotein subfraction profile: heritability and identification of quantitative trait loci. J Lipid Res 2008, 49(4): 715-23.
46. Bray, P.F., Mathias, R.A., Faraday, N. et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost 2007, 5(8): 1617-23. (Pubitemid 47091401)
47. Franchini, M., Peyvandi, F., Mannucci, P.M. The genetic basis of coronary artery disease: from candidate genes to whole genome analysis. Trends Cardiovasc Med 2008, 18(5): 157-62.
48. Madamanchi, N.R., Tchivilev, I., Runge, M. Genetic markers of oxidative stress and coronary atherosclerosis. Curr Atheroscler Rep 2006, 8(3): 177-83.
49. Hamsten, A., Eriksson, P. Identifying the susceptibility genes for coronary artery disease: from hyperbole through doubt to cautious optimism. J Intern Med 2008, 263(5): 538-52.
50. Arking, D.E., Chakravarti, A. Understanding cardiovascular disease through the lens of genome-wide association studies. Trends Genet 2009, 25(9): 387-94.
51. Vasan, R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113(19): 2335-62.
52. Dinauer, M.C., Pierce, E.A., Bruns, G.A., Curnutte, J.T., Orkin, S.H. Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 1990, 86(5): 1729-37.
53. Parkos, C.A., Dinauer, M.C., Walker, L.E., Allen, R.A., Jesaitis, A.J., Orkin, S.H. Primary structure and unique expression of the 22-kilodalton light chain of human neutrophil cytochrome b. Proc Natl Acad Sci U S A 1988, 85(10): 3319-23.
54. de Boer, M., de Klein, A., Hossle, J.P., Seger, R., Corbeel, L., Weening, R.S., Roos, D. Cytochrome b558-negative, autosomal recessive chronic granulomatous disease: two new mutations in the cytochrome b558 light chain of the NADPH oxidase (p22-phox). Am J Hum Genet 1992, 51(5): 1127-35.
55. Roos, D., De Boer, M., De Klein, A., Bolscher, B.G., Weening, R.S. Chronic granulomatous disease: mutations in cytochrome b558. Immunodeficiency 1993, 4(1-4): 289-301.
56. Moreno, M.U., San Jose, G., Orbe, J., Paramo, J.A., Beloqui, O., Diez, J., Zalba, G. Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett 2003, 542(1-3): 27-31.
57. San Jose, G., Moreno, M.U., Olivan, S., Beloqui, O., Fortuno, A., Diez, J., Zalba, G. Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension 2004, 44(2): 163-9.
58. Kokubo, Y., Iwai, N., Tago, N. et al. Association analysis between hypertension and CYBA, CLCNKB, and KCNMB1 functional polymorphisms in the Japanese population - the Suita Study. Circ J 2005, 69(2): 138-42.
59. Sales, M.L., Ferreira, M.C., Leme, C.A., Jr. et al. Non-effect of p22-phox -930A/G polymorphism on end-organ damage in Brazilian hypertensive patients. J Hum Hypertens 2007, 21(6): 504-6.
60. Lim, S.C., Goh, S.K., Lai, Y.R. et al. Relationship between common functional polymorphisms of the p22phox gene (-930A > G and +242C > T) and nephropathy as a result of Type 2 diabetes in a Chinese population. Diabet Med 2006, 23(9): 1037-41.
61. Mehranpour, P., Wang, S.S., Blanco, R.R. et al. The C242T CYBA polymorphism as a major determinant of NADPH oxidase activity in patients with cardiovascular disease. Cardiovasc Hematol Agents Med Chem 2009, 7(3): 251-9.
62. Kitami, Y., Fukuoka, T., Hiwada, K., Inagami, T. A high level of CCAAT-enhancer binding protein-delta expression is a major determinant for markedly elevated differential gene expression of the platelet-derived growth factor-alpha receptor in vascular smooth muscle cells of genetically hypertensive rats. Circ Res 1999, 84(1): 64-73.
63. Poli, V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem 1998, 273(45): 29279-82.
64. Takata, Y., Kitami, Y., Yang, Z.H., Nakamura, M., Okura, T., Hiwada, K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res 2002, 91(5): 427-33.
65. Sato, Y., Nishio, Y., Sekine, O. et al. Increased expression of CCAAT/enhancer binding protein-beta and -delta and monocyte chemoattractant protein-1 genes in aortas from hyperinsulinaemic rats. Diabetologia 2007, 50(2): 481-9.
66. Moreno, M.U., San Jose, G., Fortuno, A. et al. A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension. J Hypertens 2007, 25(8): 1620-6.
67. Schafer, M., Schafer, C., Ewald, N., Piper, H.M., Noll, T. Role of redox signaling in the autonomous proliferative response of endothelial cells to hypoxia. Circ Res 2003, 92(9): 1010-5.
68. Hulten, L.M., Levin, M. The role of hypoxia in atherosclerosis. Curr Opin Lipidol 2009, 20(5): 409-14.
69. Ben-Shoshan, J., Afek, A., Maysel-Auslender, S., Barzelay, A., Rubinstein, A., Keren, G., George, J. HIF-1alpha overexpression and experimental murine atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29(5): 665-70.
70. Mayr, M., Sidibe, A., Zampetaki, A. The paradox of hypoxic and oxidative stress in atherosclerosis. J Am Coll Cardiol 2008, 51(13): 1266-7.
71. Nangaku, M., Inagi, R., Miyata, T., Fujita, T. Angiotensin-induced hypoxia in the kidney: functional and structural changes of the renal circulation. Adv Exp Med Biol 2007, 618: 85-99.
72. Page, E.L., Chan, D.A., Giaccia, A.J., Levine, M., Richard, D.E. Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2008, 19(1): 86-94.
73. Wyche, K.E., Wang, S.S., Griendling, K.K. et al. C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 2004, 43(6): 1246-51.
74. Moreno, M.U., San Jose, G., Fortuno, A., Beloqui, O., Diez, J., Zalba, G. The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens 2006, 24(7): 1299-306.
75. Guzik, T.J., West, N.E., Black, E., McDonald, D., Ratnatunga, C., Pillai, R., Channon, K.M. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000, 102(15): 1744-7.
76. Schirmer, M., Hoffmann, M., Kaya, E., Tzvetkov, M., Brockmoller, J. Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. Pharmacogenomics J 2008, 8(4): 297-304.
77. Kuroda, J., Kitazono, T., Ago, T. et al. NAD(P)H oxidase p22phox C242T polymorphism and ischemic stroke in Japan: the Fukuoka Stroke Registry and the Hisayama study. Eur J Neurol 2007, 14(10): 1091-7.
78. San Jose, G., Fortuno, A., Beloqui, O., Diez, J., Zalba, G. NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clin Sci (Lond) 2008, 114(3): 173-82.
79. Raijmakers, M.T., Roes, E.M., Steegers, E.A., Peters, W.H. The C242T-polymorphism of the NADPH/NADH oxidase gene p22phox subunit is not associated with pre-eclampsia. J Hum Hypertens 2002, 16(6): 423-5.
80. Doi, K., Noiri, E., Nakao, A., Fujita, T., Kobayashi, S., Tokunaga, K. Haplotype analysis of NAD(P)H oxidase p22 phox polymorphisms in end-stage renal disease. J Hum Genet 2005, 50(12): 641-7.
81. Hayaishi-Okano, R., Yamasaki, Y., Kajimoto, Y. et al. Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. Diabetes Care 2003, 26(2): 458-63.
82. Hodgkinson, A.D., Millward, B.A., Demaine, A.G. Association of the p22phox component of NAD(P)H oxidase with susceptibility to diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2003, 26(11): 3111-5.
83. Matsunaga-Irie, S., Maruyama, T., Yamamoto, Y. et al. Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. Diabetes Care 2004, 27(2): 303-7.
84. Shimokata, K., Yamada, Y., Kondo, T. et al. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis 2004, 172(1): 167-73.
85. He, M.A., Cheng, L.X., Jiang, C.Z. et al. Associations of polymorphism of P22(phox) C242T, plasma levels of vitamin E, and smoking with coronary heart disease in China. Am Heart J 2007, 153(4): 640 e1-6.
86. Fan, M., Kahonen, M., Rontu, R. et al. The p22phox C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study. Am Heart J 2006, 152(3): 538-42.
87. Inoue, N., Kawashima, S., Kanazawa, K., Yamada, S., Akita, H., Yokoyama, M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998, 97(2): 135-7.
88. Nasti, S., Spallarossa, P., Altieri, P. et al. C242T polymorphism in CYBA gene (p22phox) and risk of coronary artery disease in a population of Caucasian Italians. Dis Markers 2006, 22(3): 167-73.
89. Delles, C., Zimmerli, L.U., McGrane, D.J. et al. Vascular stiffness is related to superoxide generation in the vessel wall. J Hypertens 2008, 26(5): 946-55.
90. Arca, M., Conti, B., Montali, A. et al. C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler Thromb Vasc Biol 2008, 28(4): 752-7.
91. Ueno, T., Watanabe, H., Fukuda, N. et al. Influence of genetic polymorphisms in oxidative stress related genes and smoking on plasma MDA-LDL, soluble CD40 ligand, E-selectin and soluble ICAM1 levels in patients with coronary artery disease. Med Sci Monit 2009, 15(7): CR341-8.
92. Di Castelnuovo, A., Soccio, M., Iacoviello, L. et al. The C242T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and a meta-analysis. Thromb Haemost 2008, 99(3): 594-601.
93. Inoue, N. Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 2006, 6(4): 227-31.
94. Zafari, A.M., Davidoff, M.N., Austin, H., Valppu, L., Cotsonis, G., Lassegue, B., Griendling, K.K. The A640G and C242T p22(phox) polymorphisms in patients with coronary artery disease. Antioxid Redox Signal 2002, 4(4): 675-80.
95. Gardemann, A., Mages, P., Katz, N., Tillmanns, H., Haberbosch, W. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis 1999, 145(2): 315-23.
96. Bedard, K., Attar, H., Bonnefont, J. et al. Three common polymorphisms in the CYBA gene form a haplotype associated with decreased ROS generation. Hum Mutat 2009, 30(7): 1123-33.
97. Park, J.Y., Ferrell, R.E., Park, J.J., Hagberg, J.M., Phares, D.A., Jones, J.M., Brown, M.D. NADPH oxidase p22phox gene variants are associated with systemic oxidative stress biomarker responses to exercise training. J Appl Physiol 2005, 99(5): 1905-11.
98. Niemiec, P., Zak, I., Wita, K. The 242T variant of the CYBA gene polymorphism increases the risk of coronary artery disease associated with cigarette smoking and hypercholesterolemia. Coron Artery Dis 2007, 18(5): 339-46.
99. Watkins, H., Farrall, M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 2006, 7(3): 163-73.
100. Corsetti, J.P., Ryan, D., Moss, A.J., Zareba, W., Sparks, CE. NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients. Atherosclerosis 2008, 196(1): 461-8.
101. Cahilly, C., Ballantyne, C.M., Lim, D.S., Gotto, A., Marian, A.J. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res 2000, 86(4): 391-5.
102. Spence, M.S., McGlinchey, P.G., Patterson, C.C. et al. Investigation of the C242T polymorphism of NAD(P)H oxidase p22 phox gene and ischaemic heart disease using family-based association methods. Clin Sci (Lond) 2003, 105(6): 677-82.
103. Renner, W., Schallmoser, K., Gallippi, P., Krauss, C., Toplak, H., Wascher, T.C., Pilger, E. C242T polymorphism of the p22 phox gene is not associated with peripheral arterial occlusive disease. Atherosclerosis 2000, 152(1): 175-9.
104. Grahl, D.A., Axelsson, J., Nordfors, L. et al. Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. Blood Purif 2007, 25(2): 210-8.
105. Matsunaga, S., Maruyama, T., Yamada, S., Motohashi, Y., Shigihara, T., Shimada, A., Saruta, T. Nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) P22 Phox C242T gene polymorphism in type 1 diabetes. Ann N Y Acad Sci 2003, 1005: 324-7.
106. Perianayagam, M.C., Liangos, O., Kolyada, A.Y. et al. NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol 2007, 18(1): 255-63.
107. Schachinger, V., Britten, M.B., Dimmeler, S., Zeiher, A.M. NADH/NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function. Eur Heart J 2001, 22(1): 96-101.
108. Schneider, M.P., Hilgers, K.F., Huang, Y., Delles, C., John, S., Oehmer, S., Schmieder, R.E. The C242T p22phox polymorphism and endothelium-dependent vasodilation in subjects with hypercholesterolemia. Clin Sci (Lond) 2003, 105(1): 97-103.
109. Fricker, R., Hesse, C., Weiss, J. et al. Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation. Br J Clin Pharmacol 2004, 58(2): 169-77.
110. Genius, J., Grau, A.J., Lichy, C. The C242T polymorphism of the NAD(P)H oxidase p22phox subunit is associated with an enhanced risk for cerebrovascular disease at a young age. Cerebrovasc Dis 2008, 26(4): 430-3.
111. Ito, D., Murata, M., Watanabe, K., Yoshida, T., Saito, I., Tanahashi, N., Fukuuchi, Y. C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000, 31(4): 936-9.
112. Krex, D., Ziegler, A., Konig, I.R., Schackert, H.K., Schackert, G. Polymorphisms of the NADPH oxidase P22PHOX gene in a Caucasian population with intracranial aneurysms. Cerebrovasc Dis 2003, 16(4): 363-8.